The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 16, Issue 10, 2014, Pages 1036-1039

  Heise, Tim ^a   Larbig, M ^b   Patel, S ^c   Seck, T ^b   Hehnke, U ^b   Woerle, H J ^b   Dugi, K ^b  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c BOEHRINGER INGELHEIM LTD   (United Kingdom)

Author keywords

Beta cell; DPP IV inhibitor; Drug mechanism; Glycaemic control; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; PLACEBO; ANTIDIABETIC AGENT; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; BODY MASS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HYPERGLYCEMIA; META ANALYSIS; METABOLISM; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; POSTPRANDIAL PERIOD; PURINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84912520644     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12312     Document Type: Letter

References (13)

1. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44: 1249-1258.
2. Kahn SE, Lachin JM, Zinman B et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes 2011; 60: 1552-1560.
3. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124: S3-S18.
4. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
5. Rauch T, Graefe-Mody U, Deacon CF et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther 2012; 3: 10.
6. Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves beta-cell mass in non-obese diabetic mice. J Endocrinol 2012; 214: 381-387.
7. Shah P, Ardestani A, Dharmadhikari G et al. The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab 2013; 98: E1163-E1172.
8. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
9. Foley JE, Bunck MC, Moller-Goede DL et al. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011; 54: 1985-1991.
10. Henry RR, Smith SR, Schwartz SL et al. Effects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 850-858.
11. Pratley RE, Schweizer A, Rosenstock J et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008; 10: 931-938.
12. Utzschneider KM, Tong J, Montgomery B et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008; 31: 108-113.
13. Xu L, Man CD, Charbonnel B et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008; 10: 1212-1220.